Johnson & Johnson (JNJ): Price and Financial Metrics
JNJ Stock Summary
- Johnson & Johnson's market capitalization of $437,911,771,880 is ahead of 99.75% of US-listed equities.
- JNJ's went public 35.33 years ago, making it older than 92.8% of listed US stocks we're tracking.
- The volatility of Johnson & Johnson's share price is greater than that of only 3.24% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to JNJ, based on their financial statements, market capitalization, and price volatility, are JPM, WMT, MA, UNH, and DIS.
- JNJ's SEC filings can be seen here. And to visit Johnson & Johnson's official web site, go to www.jnj.com.
JNJ Stock Price Chart Interactive Chart >
JNJ Price/Volume Stats
| Current price | $165.18 | 52-week high | $173.65 |
| Prev. close | $166.59 | 52-week low | $133.65 |
| Day low | $164.62 | Volume | 7,232,900 |
| Day high | $166.28 | Avg. volume | 8,272,644 |
| 50-day MA | $161.84 | Dividend yield | 2.45% |
| 200-day MA | $153.30 | Market Cap | 434.87B |
Johnson & Johnson (JNJ) Company Bio
Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.
JNJ Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $165.18 | $73.32 | -56% |
Below please find a table outlining a discounted cash flow forecast for JNJ, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Johnson & Johnson ranked in the 35th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 55.83%. As for the metrics that stood out in our discounted cash flow analysis of Johnson & Johnson, consider:
- As a business, JNJ is generating more cash flow than 98.14% of positive cash flow stocks in the Healthcare.
- The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than only 23.35% of the free cash flow producing stocks we're observing.
- JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 38.15% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -57% |
| 1% | -56% |
| 2% | -56% |
| 3% | -56% |
| 4% | -55% |
| 5% | -55% |
ICUI, ABC, AMPH, AZN, and NVS can be thought of as valuation peers to JNJ, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Latest JNJ News From Around the Web
Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.
JNJ COVID-19 vaccine: South Africa to resume rolloutThe South African government has decided to lift the suspension imposed on the COVID-19 vaccine developed by Johnson & Johnson (JNJ), the Mail & Guardian reported.Soon after the U.S. recommended a pause on the JNJ’s vaccine citing rare cases of blood clots, South Africa also halted its use. The country had only... |
Dividends Are Definitely Back - April 2021 Brings Roaring DividendsPhoto by designer491/iStock via Getty Images Dividend investing community, I had to write this article. The blood or "dividends" are pumping through my veins. Dividend aristocrats are increasing their dividends and beating expectations. In addition, companies are increasing dividends that I would not have seen coming. Therefore, this bodes the... |
OCGN Stock: The Huge COVAXIN News Sending Ocugen Climbing TodayOCGN stock is gaining Wednesday morning on news that Bharat Biotech's COVAXIN has an overall 78% efficacy rate. |
Federal Inspectors Say More Vaccines at Troubled Plant May Be ContaminatedLast month, up to 15 million doses of Johnson & Johnson’s vaccine had to be discarded at Emergent’s factory in Baltimore. A new report says problems were not fully investigated and other doses may be compromised. |
Minneapolis, Johnson & Johnson, YOLO: Your Wednesday Evening BriefingHere’s what you need to know at the end of the day. |
JNJ Price Returns
| 1-mo | 2.02% |
| 3-mo | 1.63% |
| 6-mo | 15.23% |
| 1-year | 9.09% |
| 3-year | 41.97% |
| 5-year | 66.65% |
| YTD | 5.61% |
| 2020 | 10.82% |
| 2019 | 16.22% |
| 2018 | -5.13% |
| 2017 | 24.43% |
| 2016 | 15.33% |
JNJ Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching JNJ
Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...